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Abstract
Background: There is no single, gold-standard, low-protein diet (LPD) for CKD patients; the best compliance is
probably obtained by personalization. This study tests the hypothesis that a multiple choice diet network allows
patients to attain a good compliance level, and that, in an open-choice system, overall results are not dependent
upon the specific diet, but upon the clinical characteristics of the patients.
Methods: Observational study: Three LPD options were offered to all patients with severe or rapidly progressive
CKD: vegan diets supplemented with alpha-ketoacids and essential aminoacids; protein-free food in substitution of
normal bread and pasta; other (traditional, vegan non supplemented and tailored). Dialysis-free follow-up and
survival were analyzed by Kaplan Meier curves according to diet, comorbidity and age.
Compliance and metabolic control were estimated in 147 subjects on diet at March 2015, with recent complete
data, prescribed protein intake 0.6 g/Kg/day. Protein intake was assessed by Maroni Mitch formula.
Results: Four hundreds and forty nine patients followed a LPD in December, 2007- March, 2015 (90% moderately
restricted LPDs, 0.6 g/Kg/day of protein, 10% at lower targets); age (median 70 (19–97)) and comorbidity (Charlson
index: 7) characterized our population as being in line with the usual CKD European population. Median e-GFR at
start of the diet was 20 mL/min, 33.2% of the patients were diabetics. Baseline data differ significantly across diets:
protein-free schemas are preferred by older, high-comorbidity patients (median age 76 years, Charlson index 8, GFR
20.5 mL/min, Proteinuria: 0.3 g/day), supplemented vegan diets by younger patients with lower GFR and higher
proteinuria (median age 65 years, Charlson index 6, GFR 18.9 mL/min; Proteinuria: 1.2 g/day); other diets are chosen
by an intermediate population (median age 71 years, Charlson index 6; GFR 22.5 mL/min; Proteinuria: 0.9 g/day); (p
<0.001 for age, Charlson index, proteinuria, GFR). Adherence was good, only 1.1% of the patients were lost to
follow-up and protein intake was at target in most of the cases with no differences among LPDs (protein intake: 0.
47 (0.26–0.86) g/Kg/day). After adjustment for confounders, and/or selection of similar populations, no difference in
mortality or dialysis start was observed on the different LPDs. Below the threshold of e-GFR 15 mL/min, 50% of the
patients remain dialysis free for at least two years.
Conclusion: A multiple choice LPD system may allow reaching good adherence, without competition among diets,
and with promising results in terms of dialysis-free follow-up. The advantages with respect to a non-customized
approach deserve confirmation in further comparative studies or RCTs.
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Background
To date, two main reasons for reconsidering on a global
scale the advantages of low protein diets, as a tool to retard
dialysis in younger patients and to avoid it in elderly pa-
tients, are the limited availability of dialysis in many devel-
oping countries, and the grim prognosis of elderly patients
who increasingly start dialysis in developed countries [1–3].
Low protein diets had encountered mixed fortunes in
the past and the term diet, often interpreted in a reductive
way, has been recently challenged in favor of “nutritional
therapy” in chronic kidney disease (CKD), underlining
that the approach to CKD patients should be more com-
prehensive, beyond the restriction of one or more aliments
[4, 5]. Indeed, nutritional therapies in CKD may be ad-
dressed to different goals: removing the cause or concause
of CKD (such as obesity), reducing the workload on the
remnant nephrons to slow progression, or stabilizing renal
function so as to allow longer dialysis-free survival [3–6].
Furthermore, the term “nutritional therapies” switches the
attention to therapeutic adherence or, using a more mod-
ern term, to concordance, a word that may substitute the
older term compliance [7–10]. The concepts are similar
but non identical: compliance implies the fact that the pa-
tient, “nudged or shoved”, has to follow the medical advice
(in this case, the “best possible diet”), while a concordant
attitude is centered upon patient’s preferences, and re-
quires a flexible application, in this case, of the diet best
fitting into the patient’s life [11–13].
Concordance is an appealing idea, and probably the best
way to manage chronic diseases; changing towards a
patient-centered attitude is however time consuming, may
require a dynamic approach based upon shared choices
and decisions [14–16]. As stated in a recent report of the
World health Organization: “patients need to be sup-
ported, not blamed (…); adherence is simultaneously influ-
enced by several factors (…); patient-tailored interventions
are required (…); systems and providers need to develop
means of accurately assessing not only adherence, but also
those factors that influence it.” [17].
In the MDRD study, the largest, most controversial and
fundamental RCT regarding diets in CKD, results are
quite contradictory when analyzed according to “intention
to treat” (demonstrating no advantage of being on a low
protein diet) and “per protocol”, stratified upon urea ex-
cretion (suggesting a significant reduction of progression
in patients with lower protein intake). Such a discrepancy
suggests that prescribing a diet is not enough, since pa-
tients tend to follow the diet they prefer [18, 19].
Many different low-protein diet (LPD) schemes have
been proposed in CKD: vegan-vegetarian or omnivorous,
supplemented or non-supplemented, with protein-free
commercial food or without it [20]. Schematically, most
authors distinguish between “moderate” protein restric-
tion (0.6 g of protein/Kg/day) and “very low” protein
diets (0.3 g/Kg/day); each of them may be proposed by
different schemas, with or without the allowance of un-
restricted meals [21–27].
Flexible, personalized, holistic approaches are not easily
analyzed, since by their own nature they tend to escape
from the rigidity of RCTs [28–32]. Randomization to dif-
ferent approaches (tailored versus standardized) could
highlight differences, but may be hardly feasible in single
centers, in which the option of personalization is often a
part of the approach to the continuum of CKD care. In
such a context, observational studies are more likely to
provide information on feasibility and side effects, and
may overcome some of the limits of RCTs, mainly the in-
clusion of populations that differ from the standard ones
encountered in daily practice [32, 33].
Consequently, adherence to therapy and incidence of
drop-out may represent important, albeit indirect, mea-
sures of success, since we may expect that multiple-choice
systems may allow easier identification of a concordant
strategy.
Hence, the present study was undertaken to test the hy-
pothesis that a multiple choice diet system in which pa-
tients are free to choose (and change) the most suitable
LPD from among several options, could allow an overall
good therapeutic adherence to LPDs. We analyzed a large
single-center cohort of on-diet patients (449 patients, 847
patient-years of observation, in which diets, mainly with a
moderate protein restriction, and controls follow a per-
sonalized schedule of prescriptions and check-ups,
adapted to the various clinical situations [20, 33–36].
Methods
Study setting; patient selection and inclusion criteria
The study was carried out at the out-patient Nephrology
Unit of the San Luigi Hospital, University of Torino, Italy.
The Unit started its activity on 1st December, 2007, and by
31st March, 2015, over 4000 patients had been evaluated.
CKD was defined according to the usual definitions of
the K/DOQI clinical practice guidelines; e-GFR was
assessed by the CKD-EPI equation, and compliance to the
protein intake by the Maroni-Mitch formula [37–39].
In the study setting, an LPD is routinely proposed by
the nephrologist to all pre-dialysis patients with CKD
stages 4-5, and to those with rapid progression of CKD
stage 3 and/or with refractory nephrotic syndrome, in
the absence of contraindications, as elsewhere described
more in detail [33].
Diets and controls
Over time, the approach to LPDs shifted from the pro-
posal of two main LPDs (0.6 g/Kg/day: vegan-vegetarian
supplemented with alpha-ketoacids and aminoacids
(LPD-AK) and with protein-free commercial food (LPD-
PFF)), which were eventually merged into one very-low
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protein diet (vLPD), to a more integrated choice includ-
ing different combinations of the previous diets and
vegan non-supplemented diets [20, 33–36] (Table 1).
All diets share a simplified and flexible approach aimed
at facilitating integration into daily life. The LPD prescrip-
tion is qualitative: it is based on allowed and forbidden
foods, with 1-3 unrestricted meals per week (depending
on the patients’ preferences and kidney function) [33].
The first diet prescribed in our Unit is a moderately re-
stricted diet (on average 0.6 g/Kg/day of protein) and only
after a successful trial, in selected cases a 0.3 diet is
prescribed.
In our region, both protein-free food and Ketosteril or
Alfa-kappa are provided free of charge (maximum ex-
penditure for protein-free food: 120 euro per month).
Daily energy intake is aimed at 30–35 kcal/Kg/day; cal-
oric intake is calculated on the basis of a diet journal
that is kept for 1–3 weeks. In elderly patients a caloric
intake of 25–30 kcal/Kg/day was considered acceptable,
provided that weight, albumin and bioimpedence mea-
sures remained stable.
Supplementation with calcium, vitamin D, folic acid,
vitamin B12, iron and erythropoietin is tailored according
to blood levels on the basis of the usual indications.
Biochemical exams and routine visits are scheduled every
1–2 months in stable subjects and up to once a week for
patients with severe metabolic derangements or when
GFR drops to below 7–10 mL/min. Dialysis start is de-
cided on the basis of the clinical picture (including symp-
toms such as weight loss, nausea, malnutrition, restless leg
syndrome, poorly controlled hypertension); GFR, urea
levels, water and acid-base balance, calcium-phosphate-
PTH balance, anemia and albuminemia are taken into ac-
count in the overall evaluation of the patient.
The simplified diets were originally designed and pre-
scribed by the nephrologist; between 2007 and 2012,
consultation with a dietitian was available only for com-
plex cases (overweight, underweight; specific situations
such as celiac disease or food allergy). Since 2013, a
part-time dietitian was enrolled in the team, thus ensur-
ing systematic counseling for all on-diet patients; her
support leaded also to an increase in personalized dialy-
sis schedules (LPD-Other).
Biochemical data
Biochemical parameters are always assessed in the pa-
tient’s laboratory of choice, and for about 70% of subjects
this means the General Laboratory of our hospital. Regu-
larly controlled biochemical data included serum creatin-
ine (mg/dL), BUN (mg/dL), GFR (CKD-EPI), proteinuria
(g/day); HCO3 (mmol/L), albumin (g/dL), parathyroid
hormone (PTH, pg/mL), protein intake (Maroni Mitch
formula [39]).
Table 1 The various low-protein diets offered in our Unit and included in this study
Type of diet Protein restriction
(g/Kg of body weight per day)
Main features Notes
“Traditional” 0.6–0.8 g/Kg/day; mixed protein
(animal and plant derived)
Modulated upon quantity of usual food; mainly
based on the traditional Italian regional cuisines.
Often corresponds to what elderly patients
already follow, in particular if they cook their
own food from raw ingredients.
Vegan 0.6–0.8 g/Kg/day; vegetable
protein
Protein intake in unrestricted vegan diets is on
the average 0.7–0.9 g/Kg/day; due to the
different bioavailability, a 0.7 diet roughly
corresponds to a 0.6 mixed protein diet
This diet is based upon the integration of
cereals and legumes at each meal, thus
ensuring complementarity in amino acids.
The 1–3 unrestricted meals per week are also
crucial for this goal.
Vegan
supplemented
(moderate
restriction)
0.6 g/Kg/day; vegetable protein,
supplemented with amino- and
keto-acids (Alfa-kappa or
Ketosteril)
Based upon forbidden (animal origin) and allowed
(all other) food. Animal-derived food is allowed in
unrestricted meals. Supplementation with Alfa-
kappa or Ketosteril pills is tailored upon nutritional
status and clinical situation (1:8–1:10 Kg BW)
The supplements of amino- and ketoacids
ensure protein complementarity without
need to choose among plant derived food.
Protein-free
food
0.6 g/Kg/day; mixed protein Protein-free pasta, bread and other
carbohydrates substituting for the usual bread,
pasta or rice.
Since carbohydrates are the basis of the
Mediterranean cuisine, their substitution allows
subjects to easily reach a 0.6 g/Kg/BW diet
Very low-
protein supple-
mented vegan
diet
0.3 g/Kg/day; vegetable protein
only, supplemented with Alfa-
kappa or Ketosteril, with protein-
free food
This diet is also based upon forbidden (animal
origin) and allowed (all other) food. Animal-
derived food is allowed only in “free meals” (usu-
ally no more than 1 per week) Supplementation
with Alfa-kappa or Ketosteril pills is higher (1:5
Kg BW). Carbohydrates are mainly protein-free.
This diet merges the concepts of vegan
supplemented and protein-free food. It is de-
manding and requires compliance to the high
number of pills employed in supplementation.
It is not prescribed as a “first line” diet.
Tailored
solutions
Usually 0.6 g/Kg/day, vegetable
or mixed
These solutions employ different combinations
of protein-free food, vegan diets and
supplementation.
The main reason for prescribing these diets
is to take into account patients’ needs or
preferences: an example: alternating vegan-
supplemented meal and protein-free food.
BW body weight
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For the sake of uniformity in the dosage methods, only
the results of tests performed in the General Laboratory
of the hospital in the last period of study were included in
the analysis of compliance. Furthermore, we standardized
our 24 h urine collection (at least 48 h from an unre-
stricted meal) only in 2014–2015; therefore, this analysis
was carried out in prevalent patients at March 31st, 2015,
considering the data available in our laboratory, updated
within 3 months (147 cases).
Statistical analysis
A descriptive analysis was performed as appropriate (me-
dian and range for non-parametric data, mean and standard
deviation for parametric distribution), ANOVA, Kruskal-
Wallis, Mann-Whitney, and t-test were performed accord-
ing to standard indications for continuous variables, while
risks, rates and proportions were compared using Chi-
square and Fisher's exact test.
Survival analysis was performed according to Kaplan
Meier also in order to identify the relevant covariates to
be entered into a multivariate analysis. The following co-
variates were analyzed: type of diet (intention to treat);
moderate protein restriction; vegan supplemented; with
protein-free food; other diets.
Age was dichotomized at 65 years, or analyzed with the
following strata (<64; 65–75; > = 75); comorbidity was
weighted by the Charlson index (dichotomized at 7) [40].
Significance of the differences was tested by the log-rank
test and Wilcoxon test.
Three outcomes were considered: dialysis (renal death),
mortality, combined outcome (death or dialysis). The be-
ginning of the observation period was either the start of
the diet or referral to the Unit for patients who were
already on LPDs. The end of observation was the end of
the diet. A separate analysis was performed starting with
the observation at the first recording of GFR < 10 or
<15 mL/min (considered “late-conventional” and “early”
start of dialysis, respectively).
Multivariate and stratified analysis
Survival analysis: Cox analysis was performed considering
the following covariates: Charlson index (dichotomized at
7); type of diet (first diet, following an intention to treat
analysis; due to the heterogeneity of the “other” diets, we
included only the two main ones: LPD-AK and LPD-PFF
in the analysis); GFR (dichotomized at 30 mL/min) and
proteinuria (dichotomized at 1 g/day) at the start of the
diet. Age, which is included in the Charlson index, was
not entered in the model due to co-linearity.
For the analysis of dialysis start, to account for the at-
trition bias of death versus the risk of starting dialysis
(competitive mortality), we selected a homogeneous
group of subjects with regard to age, comorbidity, and
kidney function (age > =65–<80 years; Charlson index >
=5–<12, baseline proteinuria <3 g/day, initial GFR >
=15–<30 mL/min). Diet, Charlson index and GFR were
entered into the Cox analysis.
Ethical issues
Informed consent was obtained for anonymous manage-
ment of the clinical data. Individual consent for publica-
tion was not needed for this study, dealing with overall
data and not with single cases.
The observational study design (PROTEREne: PRO-
TEin REductio to protect the REins) based on standard
clinical practice, that includes patients with severe CKD,
was approved by the Ethics Committee of the San Luigi
Hospital, University of Torino (Delibera 22, 18 January
2013, protocol 000037).
Results
Baseline data
Patients who opted for different diets have different base-
line characteristics (Table 2). Patients who choose a low
protein vegan supplemented diet (LPD-KA) are signifi-
cantly younger, with lower comorbidity and higher preva-
lence of glomerulonephritis, nephrotic proteinuria and
severely impaired GFR, as compared to patients who se-
lect an LPD based upon the substitution of the usual car-
bohydrates with protein-free food (LPD-PFF). The latter
are significantly older, their kidney diseases are more often
linked to cardiovascular impairment, and glomerulone-
phritides are seldom encountered. Followers of the “other”
options, more recently implemented in the system, includ-
ing vegan or Mediterranean diets, are in the intermediate
age and comorbidity group (Table 2).
Main outcomes
The main outcomes are unevenly distributed, related to
the first diet that was chosen (Table 3). Half of the pa-
tients are still on an LPD at the time of this study (225
patients); thanks to-choose the flexible approach only
few patients discontinued the diet or were lost to follow-
up (5 cases, 1.1%).
As expected by the baseline distribution, death is the
most common cause of discontinuation on LPD-PFF
(patients are about 10 years older and with higher co-
morbidity); dialysis start is the most common cause of
discontinuation in patients who start on an LPD-KA, in
keeping with a longer life-expectancy of these younger
patients, one third of whom are affected by glomerular
or systemic diseases. The heterogeneous group of pa-
tients who chose other schedules lies between these first
two as for age and comorbidity; however, serum creatin-
ine is lower and e-GFR higher in this subset of cases,
reflecting a slow and cautious integration of the new
LPD approaches in the context of a well established use
of the previous two schemes (LPD-KA and LPD-PFF).
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The attrition bias due to the competition between
mortality and dialysis start is highlighted in Fig. 1: the
patients with higher mortality (higher Charlson index,
older age) have a lower risk of dialysis start. Accordingly,
the two main diets, LPD-PFF and LPD-KA, have oppos-
ite patterns with respect to mortality (higher in the
former) and dialysis (higher in the latter).
Cardiovascular diseases are the most common cause
of death, as expected by the comorbidity burden (pa-
tients who died: median Charlson index at start of the
diet: 9) (Table 4).
Patients who start dialysis are significantly younger
and with less comorbidity than those who die (Tables 4
and 5). Of note, only 3 patients started unplanned dialy-
sis (in 1 case because of the rupture of a polycystic kid-
ney and in 2 because of fluid overload; the two latter
subjects already had an AV fistula and dialysis was
started on the day of a planned clinical visit) (Table 5).
Patient survival: Cox analysis
According to Cox analysis, which was performed consid-
ering only the two most frequent diets with comparable
Table 2 Baseline characteristics of the population, on the basis of the first diet
First diet Vegan supplemented With protein- free food Other All cases p Among groups
n 215 159 75 449
Males (%) 144 (67.0%) 98 (61.6%) 34 (45.3%) 276 (61.5%) 0.004
Females (%) 71 (33.0%) 61 (38.4%) 41 (54.7%) 173 (38.5%)
Age: median (min-max) 65 (19–86) 76 (26–97) 71 (23–88) 70 (19–97) <0.001
Age over 65 (%) 100 (46.5%) 132 (83%) 42 (56%) 274 (61%) <0.001
Age over 80 (%) 15 (7.0%) 44 (27.7%) 14 (18.7%) 73 (16.3%) <0.001
Charlson: median (min-max) 6 (2–12) 8 (2–13) 6 (2–12) 7 (2–13) <0.001
Charlson > =7 (%) 91 (42.3%) 118 (74.2%) 37 (49.3%) 246 (54.8%) <0.001
Charlson > =10 (%) 17 (7.9%) 42 (26.4%) 12 (16.0%) 71 (15.8%) <0.001
Diabetes (%) 59 (27.4%) 70 (44%) 20 (26.7%) 149 (33.2%) 0.001
Cardiopathy (%) 79 (36.7%) 100 (62.9%) 29 (38.7%) 208 (46.3%) <0.001
Neoplasia (%) 41 (19.1%) 33 (20.8%) 23 (30.7%) 97 (21.6%) 0.104
sCreatinine (mg/dL) median (min-max) 3.05 (0.6–16) 2.65 (1.0–7) 2.49 (0.6–6.7) 2.8 (0.6–16) <0.001
eGFR-EPI (mL/min) median (min-max) 18.9 (3–126) 20.5 (6.6–73) 22.5 (5.7–127) 20.0 (3–127) 0.014
GFR <15 mL/min at enrolment n (%) 80 (37.6%) 32 (20.1%) 13 (17.3%) 125 (28%) <0.001
GFR <10 mL/min at enrolment n (%) 29 (13.6%) 10 (6.3%) 5 (6.7%) 44 (9.8%) 0.038
Proteinuria (g/day)
median (min-max)
1.2 (0.1–10) 0.3 (0.1–7) 0.9 (0.1–11) 0.8 (0.1–11) <0.001
Proteinuria > = 1 g/day (%) 125 (58.7%) 41 (26.1%) 36 (48.0%) 202 (45.4%) <0.001
Proteinuria > = 3 g/day (%) 50 (23.5%) 18 (11.5%) 14 (18.7%) 82 (18.4%) 0.013
Glomerulonephritis-systemic disease (%) 67 (31.2%) 12 (7.5%) 16 (21.3%) 95 (21.2%) <0.001
Nephroangiosclerosis and/or diabetes (%) 100 (46.5%) 128 (80.5%) 37 (49.3%) 265 (59.0%) <0.001
ADPKD (%) 13 (6.0%) 4 (2.5%) 7 (9.3%) 24 (5.3%) 0.079
Charlson Charlson’s comorbidity index, E-GFR EPI GFR according to the CKD-EPI equation, ADPKD autosomal dominant polycystic kidney disease
Table 3 Main outcomes: distribution based on the first diet
First diet Vegan supplemented With protein-free food Other All cases p Among groups
Continues n (%) 86 (40.0%) 81 (50.9%) 58 (77.3%) 225 (50.1%) <0.001
Discontinued n(%) 6 (2.8%) 2 (1.3%) 0 8 (1.8%)
Transferred n (%) 4 (1.9%) 1 (0.6%) 1 (1.3%) 6 (1.3%)
Lost to follow-up n (%) 1 (0.5%) 4 (2.5%) 0 5 (1.1%)
On dialysis n (%) 83 (38.6%) 12 (7.5%) 10 (13.3%) 105 (23.4%)
Dead n (%) 35 (16.3%) 59 (37.1%) 6 (8.0%) 100 (22.3%)
Overall follow-up (years) 375.67 335 136.5 847.17 0.124
9 further deaths were recorded in the first year after discontinuation of the diet; all occurred on dialysis (on further 94.4 years of observation)
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follow-up (LPD-KA and LPD-PFF, both with over 300
patient-years of observation), survival is significantly af-
fected by Charlson index, but neither the diet nor kidney
function or proteinuria at baseline retained a significant
effect (Table 6).
Dialysis start: the effect of the diet in selected subsets of
homogeneous cases
Table 7 summarizes the analysis performed on a se-
lected population (age > =65 and <80 years; Charlson
index >4 and <12, baseline proteinuria < 3 g/day and
Fig. 1 Patient survival and “renal survival” according to the diet chosen
Table 4 Characteristics of the patients who died, stratified on the basis of the first diet
First diet Vegan supplemented With protein- free food Other All cases p Among groups
n 35 59 6 100
Males/Females (%) 29 (82.9%)
6 (17.1%)
38 (64.4%)
21 (35.6%)
5 (83.3%)
1 (16.7%)
72 (72.0%)
28 (28.0%)
0.128
Age at start of the diet median (min-max) 71 78 70 74 0.003
Charlson index median (min max) 9 (6–12) 9 (5–12) 8 (2–11) 9 (2–12) 0.794
Charlson > =7 (%) 30 (85.7%) 53 (89.8%) 4 (66.7%) 87 (87.0%) 0.264
Charlson > =10 (%) 9 (25.7%) 19 (32.2%) 2 (33.3%) 30 (30.0%) 0.789
Diabetes (%) 17 (48.6%) 30 (50.8%) 3 (50.0%) 50 (50.0%) 0.977
Cardiopathy (%) 27 (77.1%) 49 (83.1%) 4 (66.7%) 80 (80.0%) 0.552
Neoplasia (%) 9 (25.7%) 12 (20.3%) 1 (16.7%) 22 (22.0%) 0.788
s Creatinine (mg/dL) median, (min-max) 3.0 1.6–5 2.5 1.1–5.9 3.65 2.6–4.3 2.90 1.1–5.9 0.002
eGFR-EPI (mL/min) median, (min-max) 18.9 10.9–44.5 20.8 7.7–73.1 16.0 10.3–17.7 20.0 7.7–73.1 0.022
Proteinuria (g/day) median, (min-max) 0.5 0.1–4.6 0.2 0.1–6.3 0.2 0.1–1.0 0.35 0.1–6.3 0.111
Proteinuria > = 1 g/day (%) 12 (34.3%) 13 (22.8%) 1 (16.7%) 26 (26.0%) 0.410
Glomerulonephritis-systemic disease (%) 3 (8.6%) 1 (1.7%) 0 4 (4%) 0.226
Nephroangiosclerosis and/or diabetes (%) 30 (85.7%) 52 (88.1%) 4 (66.7%) 86 (86%) 0.352
Main causes of death
Cardiovascular (%) 16 (45.7%) 29 (49.1%) 2 (33.3%) 47 (47%) 0.590
Neoplasia (%) 4 (11.4%) 3 (5.1%) 1 (16.7%) 8 (8%)
Lung disease (%) 1 (2.8%) 4 (6.7%) 0 5 (5%)
Infection (%) 4 (11.4%) 5 (8.5%) 0 9 (9%)
Other (%) 6 (17.1%) 5 (8.5%) 2 (33.3%) 13 (13%)
Unknown (%) 4 (11.4%) 13 (22.1%) 1 (16.7%) 18 (18%)
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GFR at start between 15 and 30 mL/min), chosen to
try to overcome the attrition bias of mortality, given
the baseline differences by self-allocation of different
patients to different diets (Table 2). According to this
analysis, there is no difference according to LPD, and
only proteinuria retains a significant effect on renal
survival (Fig. 2: outcome ESRD or death in the se-
lected population).
Compliance and metabolic control
Table 8 reports the main biochemical data in a prevalent
subset of the on-diet population (on a 0.6 g/Kg/day diet)
Table 5 Characteristics of the patients who started dialysis (listed on the basis of the first diet)
First diet Vegan supplemented With protein- free food Other All cases p Among groups
n 83 12 10 105
Males/Females (%) 52 (62.7%)
31 (37.3%)
8 (66.7%)
4 (33.3%)
4 (40.0%)
6 (60.0%)
64 (61.0%)
41 (39.0%)
0.348
Age at start of diet: median (min max) 63 (23–86) 72 (59–86) 69.5 (29–83) 64 (23–86) 0.009
Age over 65 (%) 32 (38.6%) 9 (75.0%) 6 (60.0%) 47 (44.8%) 0.036
Age over 80 (%) 4 (4.8%) 2 (16.7%) 1 (10.0%) 7 (6.7%) 0.278
Charlson index median (min max) 6 (2–11) 7.5 (5–12) 8 (4–10) 6 (2–12) 0.001
Charlson > =7 (%) 30 (36.1%) 9 (75.0%) 8 (80.0%) 47 (44.8%) 0.003
Charlson > =10 (%) 5 (6.0%) 3 (25.0%) 1 (10.0%) 9 (8.6%) 0.089
Diabetes (%) 23 (27.7%) 7 (58.3%) 4 (40.0%) 34 (32.4%) 0.091
Cardiopathy (%) 26 (31.3%) 6 (50.0%) 6 (60.0%) 38 (36.2%) 0.117
Neoplasia (%) 16 (19.3%) 2 (16.7%) 6 (60.0%) 24 (22.9%) 0.013
s Creatinine (mg/dL) median, (min-max) 4.5 (1.5–16.0) 3.3 (2.3–6.4) 3.6 (2.5–6.7) 4.2 (1.5–16.0) 0.492
eGFR-EPI (mL/min) median, (min-max) 12.8 (3.0–44.6) 16.2 (7.7–25.5) 15.1 (5.7–19.7) 13.2 (3.0–44.6) 0.885
Proteinuria (g/day) median, (min-max) 1.5 (0.1–9) 1.4 (0.7–5.7) 3.3 (0.1–11) 1.5 (0.1–11) 0.407
Proteinuria > =1 g/day (%) 55 (67.9%) 8 (66.7%) 7 (70.0%) 70 (68.0%) 0.986
Proteinuria > =3 g/day (%) 21 (25.9%) 4 (33.3%) 5 (50.0%) 30 (29.1%) 0.270
Glomerulonephritis-systemic disease (%) 26 (31.3%) 2 (16.7%) 2 (20.0%) 30 (28.6%) 0.472
Nephroangiosclerosis and/or diabetes (%) 37 (44.6%) 10 (83.3%) 5 (50.0%) 52 (49.5%) 0.043
ADPKD (%) 7 (8.4%) 0 (0.0%) 2 (20.0%) 9 (8.6%) 0.247
Type of dialysis (% HD) 71 (85.5%) 10 (83.3%) 10 (100%) 91 (86.6%) 0.457
dialysis in emergency n (%) 3 (3.6%) 0 0 3 (2.8%) 0.630
Table 6 Crude and adjusted HRs of mortality, by diet, Charlson index, proteinuria, and GFR (Cox analysis) (LPD-KA and LPD-PFF)
n/N Crude RR (95% CIs) p value Adjusted HR (95% CIs) p value
Diet
LPD-KA 37/215 1 (−) <0.0001 1 (−) 0.5264
LPD-PFF 59/159 2.16 (1.51–3.08) 1.15 (0.75–1.75)
Charlson index <0.0001
<7 12/165 1 (−) <0.0001 1 (−)
≥7 84/209 5.53 (3.13–9.77) 6.11 (3.28–11.36)
Proteinuria
(g/day) <0.0001 0.2107
< 1 69/207 1 (−) 1 (−)
≥ 1 27/167 0.49 (0.33–0.72) 0.75 (0.48–1.18)
GFR (ml/m) 0.2425
< 30 78/291 1 (−) 0.3436 1 (−)
≥ 30 18/83 0.81 (0.72–1.27) 0.74 (0.44–1.23)
GFR-EPI Glomerular filtration rate (EPI formula), RR Relative risk, HR Hazard ratio
statistically significant OR in bold
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as of March 31st, 2015, who underwent metabolic and
renal functional assessment within three months in the
general laboratory of our hospital (147 patients, out of
209 prevalent patients on a 0.6 g/Kg/day of protein diet
on follow-up at the same date). The general characteris-
tics of this subset are as expected from our enrollment
criteria: median e-GFR below 30 mL/min, about one
fourth of the patients with e-GFR <15 mL/min. Compli-
ance to the diet (0.6 g/Kg/day) assessed on a 24-h urine
collection was very good (median 0.47 g/Kg/day, per-
formed at least 48 h after the last unrestricted meal) and
more than half of the patients were slightly below the
prescribed intake. Moreover, serum albumin was within
the normal range in most cases, and the 11 patients with
serum albumin <3 g/dL were characterized by low
Charlson index (median 4, range 2–9) and high protein-
uria (median 5.6, min-max: 1.1–10.9 g/day), suggesting
that this was most likely an effect of the kidney disease
and not of malnutrition. Furthermore, parathyroid hor-
mone and bicarbonate levels were on target in most
cases, and only 5 patients (3 of whom had severe cardiac
disease and high need for diuretics) had a BUN above
100 mg/dL.
Discussion
The main point of interest in our study regards the
multiple-choice approach developed, which indirectly
demonstrated the relevance of patient’s preferences: when
patients are given various options, different categories of
individuals choose different diets (Tables 1 and 2). These
data are in keeping with previous studies by our group that
suggested, on a smaller scale, that LPD choice reflected the
patients’ characteristics: elderly patients, less willing to
change their dietary habits, prefer diets based upon the
substitution of regular carbohydrates (mainly bread and
pasta in Italy, which contain 11–12% of protein) with
protein-free food, while younger patients prefer a simpli-
fied scheme of supplemented vegan/vegetarian diets, which
are more compatible with their “social life” [20, 25, 33].
Other experts report similar data on diets based upon
protein-free food, suggesting that such an option, which is
free of charge in our country, should also be considered in
other settings [14–16, 23, 26, 41, 42].
While only larger multicenter studies, comparing (and
eventually randomizing) different approaches to protein
restriction in CKD may definitely highlight the specific
features, advantages and draw-backs of a multiple-
choice dietary approach, flexibility may be the reason
why only a minority of the patients discontinued LPDs
(1.8%), or was lost to follow-up (1.1%), while about 10%
of the subjects changed at least one diet over time
(Table 3). Likewise, it may offer an indirect explanation
to the good compliance and metabolic control observed:
an up-date involving a sample of 147 on-diet prevalent
stable subjects with complete data showed that protein
Table 7 Crude and adjusted HRs of dialysis start by main diet (LPD-KA, LPD-PFF), Charlson index, proteinuria, and GFR (Cox analysis)
in the population: age > =65–<80 years; Charlson index > =5 < 12; proteinuria <3 g/day GFR at start > =15 < 30 mL/min
n/N Crude RR (95% CIs) P value Adjusted HR (95% CIs) P value
Diet
0.19 0.2326LPD-KA 6/32 (1−) (1−)
LPD-PFF 4/46 0.46 (0.14–1.51) 0.43 (0.11–1.72)
Charlson index
0.38 0.7511<7 2/25 (1−) (1−)
≥7 8/53 1.89 (0.43–8.25) 1.31 (0.25–6.93)
Proteinuria (g/day)
0.002 0.0303<1 3/55 (1−) (1−)
≥1 7/23 5.58 (1.58–19.71) 5.13 (1.17–22.55)
RR Relative risk, HR Hazard ratio
Fig. 2 Combined outcome of patient and renal survival in a selected
population: age > =65 and <80 years; Charlson index >4 and <12,
baseline proteinuria < 3 g/day and GFR at start between 15
and 30 mL/min
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intake was even lower than recommended i.e., 0.47 ver-
sus 0.6 g/Kg/day, with satisfactory nutritional data and
metabolic data (Table 8).
Taking into account the baseline differences, it is not
surprising that both renal and patient survival differ ac-
cording to the diet chosen, here analyzed as “intention
to treat”, sorting patients according to the first diet
(Fig. 1). Patient survival was the lowest on the diet based
upon protein-free food, as expected in a significantly
older with a higher Charlson index (8, meaning a sur-
vival probability of 35% at two years) [40]. The inde-
pendence of survival form the diet choice is confirmed
by Cox analysis, that confirms the importance of
Charlson index (which includes the effect of age) and
fails to identify an effect of diet or of severity of the
kidney disease (Tables 4, 6).
Mortality represents a considerable attrition bias for
dialysis start, and “renal survival” was the lowest in the
younger population (Fig. 1); however, the differences dis-
appear in survival and multivariate analysis, when a
population at comparable risk of death is selected
(Table 7, Fig. 2).
Like all clinical studies, ours has merits and limits.
The merit is the novelty and the fact that it includes one
of the largest, currently available survival analyses re-
garding a cohort of patients treated with different LPDs,
mainly moderately restricted. It proposes to analyze
LPDs as the different dialysis choices i.e., a system and
not the sum of single treatments, in which patients are
left free to self-allocate to the treatment(s) that best fit
into their daily life, suggesting that in such a context dif-
ferences among results reflect the patients’ characteris-
tics and not the treatment options [43].
Our study is not a randomized trial; while this choice
may better reflect the clinical reality, it lacks the strength
of RCTs, and does not allow comparing with other
models of care (not flexible, or including one “best” diet
only) [28–31].
Besides the limitations shared by all non randomized
approaches, the progressive development of our system
Table 8 Compliance and main biochemical data at the (last updating): 147 on-diet patients who underwent complete biochemical
profiling by March 31st, 2015 (with a complete biochemical profile performed at the san Luigi General Laboratory)
Diet history LPD-KA only LPD-PFF only Other only More than
one diet
All patients p Among
groups
n 54 46 32 15 147
Males/Females 39 (72.2%)
15 (27.8%)
25 (54.3%)
21 (45.7%)
13 (40.6%)
19 (59.4%)
8 (53.3%)
7 (46.7%)
85 (57.8%)
62 (42.2%)
0.032
sCreatinine mg/dL: median (min-max) 2.7
1.2–8.1
3.1
1.3–11.8
2.4
1.3–11.5
2.9
1.4–8.0
2.8
1.2–11.8
0.106
Creatinine Cl. (mL/min) median (min-max) 27
6–103
18
6–59
31
10–66
13
5–57
22
5–103
0.024
Proteinuria g/day: median, (min-max) 1.25
0.1–10.9
0.33
0.1–3.4
0.86
0.1–6.4
1.1
0.1–9.8
0.79
0.1–10.9
0.004
Proteinuria≥ 1 g/day(%) 29 (53.7%) 15 (32.6%) 16 (50.0%) 8 (53.3%) 68 (46.3%) 0.162
s-albumin g/dL: median (min-max) 3.71
1.80–4.70
3.79
3.10–5.00
3.87
2.50–4.60
3.50
2.42–4.10
3.76
1.80–5.00
0.165
Albumin <3 g/dL (%) 7 (13.0%) 0 1 (3.1%) 3 (20.0%) 11 (7.5%) 0.016
PTH pg/mL: median (min-max) 77
20–333
112
34–848
104
36–705
25
21–280
99.7
20.0–848.0
0.027
PTH >300 pg/mL(%) 2 (3.8%) 5 (10.9%) 2 (6.3%) 2 (14.3%) 11 (7.6%) 0.439
BUN mg/dL, median (min-max) 44.5
11–98.5
53
9.5–111.5
38.5
17–93.5
46.5
23–100
46.5
9.5–111.5
0.076
BUN > =100 mg/dL 0 3 (6.5%) 0 2 (13.3%) 5 (3.4%) 0.031
HCO3 median, mg/dL) 25.1
14.3–31.0
26.2
17.7–39.0
25.6
17.0–34.0
24.6
20.8–28.0
25.6
14.3–39.0
0.244
HCO3 < 20 mg/dL 5 (9.8%) 3 (7.0%) 3 (10.0%) 0 11 (8.1%) 0.710
Protein intake (Mitch formula) g/Kg/day: median (min-max) 0.48
0.36–0.76
0.44
0.29–0.86
0.52
0.32–0.83
0.46
0.26–0.67
0.47
0.26–0.86
0.002
Protein <0.6 g/Kg/day 29 (54.3%) 35 (76.1%) 13 (40.6%) 10 (66.7%) 87 (59.6%) 0.013
Protein ≥0.8 g/Kg/day 0 1 (2.2%) 2 (6.3%) 0 3 (2.0%) 0.233
The 48 patients who did not complete biochemical profiling in our laboratory in the last 3 months were older and had a higher Charlson index, but with similar
creatinine, e-GFR, and diet history as compared to the whole on-diet population, thus confirming the advantage of tailoring the check-ups also considering the
patient’s needs
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doesn’t allow sound comparison with the “tailored” diet
options that were more recently developed in our Unit,
whose promising results need to be validated over al
longer follow-up.
The promising results, together with the limits of this
first experience highlight the need of a prospective mul-
ticentric analysis including various LPDs and different
diet-systems, that could be compared or to identify the
best strategies of attaining compliance.
Conclusions
Different CKD patients choose different diets; when several
options are present, a relevant percentage of patients ex-
perience more than one option; in such a system, drop-out
and loss to follow-up are exceedingly rare, and compliance
is remarkably good. While only comparing different ap-
proaches, at best with a randomized trial, can highlight the
specific merits and drawbacks of such a system, the results
obtained suggest that an option among various LPDs may
be offered to CKD patients without “competition” between
different diets, and with good clinical results.
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